Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$38.07 - $59.71 $4.6 Million - $7.21 Million
-120,700 Reduced 41.19%
172,300 $6.61 Million
Q1 2024

May 15, 2024

SELL
$55.39 - $72.47 $6.39 Million - $8.36 Million
-115,400 Reduced 28.26%
293,000 $17.2 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $3.71 Million - $6.48 Million
99,900 Added 32.38%
408,400 $24.4 Million
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $2.2 Million - $8.29 Million
92,900 Added 43.09%
308,500 $11.7 Million
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $2.2 Million - $2.68 Million
28,700 Added 15.36%
215,600 $19.6 Million
Q1 2023

May 15, 2023

SELL
$46.59 - $66.96 $409,992 - $589,248
-8,800 Reduced 4.5%
186,900 $12.3 Million
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $4.39 Million - $6.2 Million
101,500 Added 107.75%
195,700 $10.1 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $1.36 Million - $2.11 Million
30,300 Added 47.42%
94,200 $6.43 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.16B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.